RxDoctor Payments Data

Nicole Ilgenfritz

Primary Care · Bethel Park, PANPI 1912419029

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1,174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 43.6% of the total. Reporting peaked in 2022 at $4,828 and has fallen 58.8% since, to $1,989 in 2025. Among primary care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,085in general payments, 2019–2025

Across 1,174 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Novo Nordisk$3K
  • Lilly USA, LLC$1K
  • GSK$700
  • Pfizer$573
  • Biohaven Pharmaceutical Holding Company Ltd.$500
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$18,084100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,085 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$64,901
JardianceEmpagliflozin61$57,474
EliquisApixaban56$52,206
TrulicityDulaglutide48$45,646
OzempicSemaglutide27$45,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,972
XareltoRivaroxaban28$19,550
RybelsusSemaglutide12$16,897
Repatha SureclickEvolocumab31$16,079
MyrbetriqMirabegron18$11,220
KerendiaFinerenone14$8,662
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,267
LinzessLinaclotide11$6,636
FarxigaDapagliflozin Propanediol12$6,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,250$110,547101 claims
Novo NordiskOzempic, Rybelsus$3,235$62,22339 claims
Boehringer IngelheimJardiance$148$57,47461 claims
PfizerEliquis$573$52,20656 claims
GSKTrelegy Ellipta, Anoro Ellipta$700$43,23970 claims
Johnson & JohnsonXarelto$308$19,55028 claims
Astellas Pharma US IncMyrbetriq$74$11,22018 claims
BayerKerendia$187$8,66214 claims
AbbVieLinzess, Synthroid$7,884$7,32931 claims
AstraZenecaFarxiga$338$6,57112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Bethel Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →